LBO — AKRON GENERAL MEDICAL CENTER
IRR: 16.1% | MOIC: 2.11x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
16.1%
IRR
2.11x
MOIC
$1.0B
Entry EV
$1.5B
Exit EV
$536.3M
Equity Invested
Sources & Uses
S&UTotal · $1.0B| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $404.7M | 38.8% | |
| Sub Debt | $101.2M | 9.7% | |
| Equity | $536.3M | 51.5% | |
| Enterprise Value | $1.0B | 97.1% | |
| Transaction Fees | $30.4M | 2.9% | |
| Total Uses | $1.0B | 100.0% |
Interpretation
INTAt 2.11x MOIC and 16.1% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $146.6M |
| Exit Ev | $1.5B |
| Net Debt At Exit | $408.3M |
| Equity At Exit | $1.1B |
| Equity Invested | $536.3M |
| Total Value Created | $595.1M |
| Value From Growth | $477.3M |
| Value From Multiple | $50.6M |
| Value From Deleveraging | $97.6M |